Skip to main content
SpringerLink
Log in

Optimizing the treatment of unstable angina

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Unstable angina and non-Q-wave myocardial infarction (MI) are at the center of the spectrum of myocardial ischemia, which ranges from stable angina to acute Q-wave MI. In addition to clinical evaluation, cardiac specific markers such as troponin T or I can assist in early diagnosis, triage, and risk stratification. Antithrombotic therapy with aspirin and heparin have been shown to improve the outcome of patients with acute ischemic syndromes. Thrombolytic therapy does not appear to be beneficial in these syndromes. Antiischemic therapy remains an important component of the overall therapy. A strategy of early coronary angiography and revascularization leads to a similar long-term outcome as compared with a more conservative strategy of revascularization for recurrent ischemia, but the early invasive strategy is more expeditious as a large number of conservatively treated patients have recurrent ischemia. At present, many new antithrombotic agents are under active investigation, with the hope that they will lead to further improvement in the clinical outcome of patients with acute ischemic syndromes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathophysiology of coronary artery disease and the acute coronary syndromes.N Engl J Med 1992;326:242–250, 310–318.

    PubMed  Google Scholar 

  2. Falk E. Unstable angina with fatal outcome: Dynamic coronary thrombosis leading to infarction and/or sudden death.Circulation 1985;71:699–708.

    PubMed  Google Scholar 

  3. Davies MJ, Thomas A. Plaque assuring-the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina.Br Heart J 1985;53:363–373.

    PubMed  Google Scholar 

  4. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction.N Engl J Med 1980;303:897–902.

    PubMed  Google Scholar 

  5. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) Trial; phase I findings.N Engl J Med 1985;312:932–936.

    Google Scholar 

  6. DeWood MA, Stifter WF, Simpson CS, et al. Coronary arteriographic findings soon after non-Q wave myocardial infarction.N Engl J Med 1986;315:417–423.

    PubMed  Google Scholar 

  7. The TIMI IIIA Investigators. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial.Circulation 1993;87:38–52.

    Google Scholar 

  8. Sullivan E, Kearney M, Isner JM, Topol EJ, Losordo DW. Pathology of unstable angina: Analysis of biopsies obtained by directional coronary atherectomy.J Thrormb Thrombolysis 1994;1:63–71.

    Google Scholar 

  9. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease.Circulation 1990;81:491–497.

    PubMed  Google Scholar 

  10. Ambrose JA, Winters SL, Arora RR, et al. Angiographic evolution of coronary artery morphology in unstable angina.J Am Coll Cardiol 1986;7:472–478.

    PubMed  Google Scholar 

  11. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease?Circulation 1988;78:1157–1166.

    PubMed  Google Scholar 

  12. Sherman CT, Litvack F, Grundfest W, et al. Coronary angioscopy in patients with unstable angina pectoris.N Engl J Med 1986;315:913–919.

    PubMed  Google Scholar 

  13. Brunelli C, Spallarossa P, Ghigliotta G, Ianetti M, Caponnetto S. Thrombosis in refractory unstable angina.Am J Cardiol 1991;68:110B-118B.

    PubMed  Google Scholar 

  14. Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease.N Engl J Med 1986;315:983–989.

    PubMed  Google Scholar 

  15. Theroux P, Latour JG, Leger-Gautier C, Delaria J. Fibrinopeptide A and platelet factor four levels in unstable angina.Circulation 1987;75:156–162.

    PubMed  Google Scholar 

  16. Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina.N Engl J Med 1983;309:396–403.

    PubMed  Google Scholar 

  17. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin or both to treat unstable angina.N Engl J Med 1988;319:1105–1111.

    PubMed  Google Scholar 

  18. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease.Lancet 1990;336:827–830.

    Google Scholar 

  19. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial.Circulation 1994;89:81–88.

    PubMed  Google Scholar 

  20. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: Should the paradigm be expanded?Circulation 1989;79:441–444.

    PubMed  Google Scholar 

  21. Braunwald E. The open-artery theory is alive and well-again.N Engl J Med 1993;329:1650–1652.

    PubMed  Google Scholar 

  22. Cannon CP, Antman EM, Walls R, Braunwald E. Time as an adjunctive agent to thrombolytic therapy.J Thromb Thrombolysis 1994;1:27–34.

    PubMed  Google Scholar 

  23. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB Trial.Circulation 1994;89:1545–1556.

    Google Scholar 

  24. Braunwald E, Mark DB, Jones RH, et al.Unstable Angina: Diagnosis and Management. Clinical Practice Guideline No. 10. Rockville, MD: Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, U.S. Department of Health and Human Services, 1994:154.

  25. Anderson HV, Cannon CP, Stone PH, et al. One-year results of the TIMI-IIIB clinical trial. A randomized comparison of TPA vs. placebo and early invasive vs. early conservative strategies in unstable angina and non-Q-wave myocardial infarctionJ Am Coll Cardiol 1995 (in press).

  26. Cannon CP, Thompson B, McCabe CH, et al. Predictors of non-Q-wave acute myocardial infarction in patients with acute ischemic syndromes: An analysis from the Thrombolysis in Myocardial Ischemia (TIMI) III Trials.Am J Cardiol 1995;75:977–981.

    PubMed  Google Scholar 

  27. Puleo PR, Meyer D, Wathen C, et al. Use of a rapid assay of subforms of creatine kinase MB to diagnose or rule out acute myocardial infarction.N Engl J Med 1994;331:561–566.

    PubMed  Google Scholar 

  28. Puleo PR, Guadagno PA, Roberts R, et al. Early diagnosis of acute myocardial infarction based on assay for subforms of creatine kinase-MB.Circulation 1990;82:759–764.

    PubMed  Google Scholar 

  29. Adams JE, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990's?Circulation 1993;88:750–763.

    PubMed  Google Scholar 

  30. Katus HA, Remppis A, Neumann FJ, et al. Diagnostic efficiency of troponin T measurements in acute myocardial infarction.Circulation 1991;83:902–912.

    PubMed  Google Scholar 

  31. Actams JE, Bodor GS, Davila-Roman VG, et al. Cardiac troponin I: A marker with high specificity for cardiac injury.Circulation 1993;88:101–106.

    PubMed  Google Scholar 

  32. Antman EM, Grudzien C, Sacks DB. Evaluation of a rapid bedside assay for detection of serum cardiac troponin T.JAMA 1995;273:1279–1282.

    PubMed  Google Scholar 

  33. Hamm CW, Ravkilde J, Gerhardt W, et al. The prognostic value of troponin T in unstable angina.N Engl J Med 1992;327:146–150.

    PubMed  Google Scholar 

  34. Ravkilde J, Nissen H, Horder M, Thygesen K. Independent prognostic value of serum creatine kinase isoenzyme MB mass, cardiac troponin T and myosin light chain levels in suspected acute myocardial infarction. Analysis of 28 months of follow-up in 196 patients.J Am Coll Cardiol 1995;25:574–581.

    PubMed  Google Scholar 

  35. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina.N Engl J Med 1985;313:1369–1375.

    PubMed  Google Scholar 

  36. Willard JE, Lange RA, Hillis LD. The use of aspirin in ischemic heart disease.N Engl J Med 1992;327:175–181.

    PubMed  Google Scholar 

  37. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study.N Engl J Med 1989;321:129–135.

    Google Scholar 

  38. Antiplatelet Trialist' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death myocardial infarction and stroke by prolongued antiplatelet therapy in various categories of patients.Br Med J 1994;308:81–106.

    Google Scholar 

  39. Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial.Ann Intern Med 1991;114:835–839.

    PubMed  Google Scholar 

  40. Roux S, Christeller S, Ludin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: A meta-analysis.J Am Coll Cardiol 1992;19:671–677.

    PubMed  Google Scholar 

  41. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.Lancet 1988;2:349–360.

    Google Scholar 

  42. Hirsh J. Heparin.N Engl J Med 1991;324:1565–1574.

    PubMed  Google Scholar 

  43. Theroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina.Circulation 1993;88:2045–2048.

    PubMed  Google Scholar 

  44. Flaker GC, Bartolozzi J, Davis V, McCabe CH, Cannon CP. Use of a standardized nomogram to achieve therapeutic anticoagulation after thrombolytic therapy in myocardial infarction.Arch Intern Med 1994;154:1492–1496.

    PubMed  Google Scholar 

  45. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a “standard care” nomogram.Ann Intern Med 1993;119:874–881.

    PubMed  Google Scholar 

  46. Landefeld CS, Cook EF, Flateley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy.Am J Med 1987;82:703–713.

    PubMed  Google Scholar 

  47. Cannon CP, Becker RC, Loscalzo J, et al. Usefulness of APTT to predict bleeding for hirudin (and heparin) (abstr).Circulation 1994;90:I-563.

    Google Scholar 

  48. Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II trial.Ann Intern Med 1991;115:256–265.

    PubMed  Google Scholar 

  49. Bovill E, Tracy R, Granger C, Hardin N. Monitoring anticoagulant therapy in the setting of thrombolytic therapy. In: Becker RC, ed.The Modern Era of Coronary Thrombolysis. Boston: Kluwer Academic Publishers, 1994:239–251.

    Google Scholar 

  50. Granger C, White HD, Hirsh J, Woodlief L, Chesebro J, for the GUSTO Trial Investigators. Relationship of APTT to outcome after thrombolsis: Results from the GUSTO Trial (abst.),Circulation 1993;88:I-200.

    Google Scholar 

  51. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.N Engl J Med 1986;315:1109–1114.

    PubMed  Google Scholar 

  52. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time.N Engl J Med 1972;287:324–327.

    PubMed  Google Scholar 

  53. Turpie AGG, Robinson JG, Doyle DJ, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction.N Engl J Med 1989;320:352–357.

    PubMed  Google Scholar 

  54. Kaplan K, Davison R, Parker M, Mayberry B, Feiereisel P, Salinger M. Role of heparin after intravenous thrombolytic therapy for acute myocardial infarction.Am J Cardiol 1987;59:241–244.

    PubMed  Google Scholar 

  55. Camilleri JF, Bonnet JL, Bouvier JL, et al. Thrombolyse intraveineuse dans l'infarctus du myocarde: Influence de la qualité de l'anticoagulation dur le taux de récidives précoces dangor ou d'infarctus.Arch Mal Coeur 1988;81:1037–1041.

    PubMed  Google Scholar 

  56. Melandri G, Branzi A, Traini AM, Bacchi Raggiani ML, Mignatti V, Mahnani B. A prospective study of the value of monitoring heparin treatment after thrombolysis with the activated clotting time (abstr).J Am Coll Cardiol 1994; Special issue:57A.

  57. Lidon R-M, Theroux P, Juneau M, et al. The partial thromboplastin time during episodes of recurrent ischemic pain in unstable angina patients treated with heparin (abstr).Circulation 1992;86:I857.

    Google Scholar 

  58. Becker R, Tracy R, Thompson B, Mann K, Bovill E, for the TIMI MB Investigators. Anticoagulation profile in heparinized patients with unstable angina and non-Q wave myocardial infarction experiencing clinical events (abstr).Circulation 1994;90:I664.

    Google Scholar 

  59. Gottlieb SO, Weisfeldt ML, Ouyang P, et al. Effect of the addition of propranolol to therapy with nifedepine for unstable angina: A randomized, double-blind, placebo-controlled trial.Circulation 1986;73:331–337.

    PubMed  Google Scholar 

  60. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin and risk factor reduction.JAMA 1988;260:2259–2263.

    PubMed  Google Scholar 

  61. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction.N Engl J Med 1981;304:801–807.

    Google Scholar 

  62. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction, a double-blind randomized trial.Lancet 1981;2:823–827.

    PubMed  Google Scholar 

  63. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. 1. Mortality results.JAMA 1982;247:1707–1714.

    Google Scholar 

  64. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction.Lancet 1986;2:57–66.

    Google Scholar 

  65. Rizik D, Timmis GC, Grines CL, Bakalyar D, Schreiber T. Immediate use of beta blockers, but not calcium blockers, improves prognosis in unstable angina (abstr).Circulation 1991;84(Suppl II):II345.

    Google Scholar 

  66. TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial.N Engl J Med 1989;320:618–627.

    Google Scholar 

  67. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction.N Engl J Med 1988;319:385–392.

    Google Scholar 

  68. Braunwald E. Unstable angina: A classification.Circulation 1989;80:410–414.

    PubMed  Google Scholar 

  69. Maseri A. Pathogenic classification of unstable angina as a guideline to individual patient management and prognosis.Am J Med 1986;80(Suppl 4C):48–55.

    Google Scholar 

  70. Betriu A, Heras M, Cohen M, Fuster V. Unstable angina: Outcome according to clinical presentation.J Am Coll Cardiol 1992;19:1659–1663.

    PubMed  Google Scholar 

  71. Ahmed WH, Bittl JA, Braunwald E. Relation between clinical presentation and angiographic findings in unstable angina pectoris, and comparison with that in stable angina.Am J Cardiol 1993;72:544–550.

    PubMed  Google Scholar 

  72. Calvin JE, Klein LW, VandenBerg BJ, et al. Risk stratification in unstable angina. Prospective validation of the Braunwald classification.JAMA 1995;273:136–144.

    PubMed  Google Scholar 

  73. van Miltenburg-van Sijl AJM, Simoons ML, Veerhoek RJ, Bossuyt PMM. Incidence and follow-up of Braunwald subgroups in unstable angina pectoris.JAm Coll Cardiol 1995;25:1286–1292.

    Google Scholar 

  74. Simoons ML, de Boer MJ, van den Brand MJBM, et al. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina.Circulation 1994;89:596–603.

    PubMed  Google Scholar 

  75. Schulman SP, Goldschmidt-Clermont PJ, Navetta RI, et al. Integrelin in unstable angina: A double blind randomized trial (abstr).Circulation 1993;88:I608.

    Google Scholar 

  76. Theroux P, White H, David D, et al. A heparin-controlled study of MK-383 in unstable angina (abstr).Circulation 1994;90:I231.

    Google Scholar 

  77. Theroux P, Kouz S, Knudtson ML, et al. A randomized double-blind controlled trial with the non-peptidic platelet PG IIb/IIIa antagonist RO 44-9883 in unstable angina (abstr).Circulation 1994;90:I232.

    Google Scholar 

  78. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk angioplasty.N EnglJ Med 1994;330:956–961.

    Google Scholar 

  79. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months.Lancet 1994;343:881–886.

    PubMed  Google Scholar 

  80. Lincoff AM, Califf RM, Anderson K, Weisman HP, Topol EJ, for the EPIC Investigators. Striking clinical benefit with platelet GP IIb/IIIa inhibition by c7E3 among patients with unstable angina: Outcome in the EPIC trial (abstr).Circulation 1994;90:I21.

    Google Scholar 

  81. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin Ill-independent inhibitors.J Clin Invest 1990;86:385–391.

    PubMed  Google Scholar 

  82. Topol EJ, Fuster V, Harrington RA, et al. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial.Circulation 1994;89:1557–1566.

    PubMed  Google Scholar 

  83. Sharma GVRK, Lapsey D, Vita JA, et al. Usefulness and tolerability of Hirulog, a direct thrombin-inhibitor, in unstable angina pectoris.Am J Cardiol 1993;72:1357–1360.

    PubMed  Google Scholar 

  84. Lidon R-M, Theroux P, Juneau M, Adelman B, Maraganore J. Initial experience with a direct antithrombin, Hirulog, in unstable angina: Anticoagulant, antithrombotic and clinical effects.Circulation 1993;88:1495–1501.

    PubMed  Google Scholar 

  85. Fuchs J, Cannon CP, and the TIMI 7 Investigators. Hirulog in the treatment of unstable angina: Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial.Circulation, 1995;92:727–733.

    PubMed  Google Scholar 

  86. Hirsh J, Fuster V. Guide to anticoagulation therapy. Part 1: heparin.Circulation 1994;89:1449–1468.

    PubMed  Google Scholar 

  87. Hirsh J, Levine M. Low molecular weight heparin.Blood 1993;79:1–17.

    Google Scholar 

  88. Jeske W. (abstr).Blood 1993;82(Suppl I):273a.

    Google Scholar 

  89. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecularweight heparin or unfractionated heparin.N Engl J Med 1995;332:1330–1335.

    PubMed  Google Scholar 

  90. Wallentin L, Ohlsson J, Swahn E for the FRISC Study Group. Fragmin During Instability in Coronary Artery Disease (FRISC)-Short Term Results of a Placebo Controlled Prospective Randomized Study of S.C. Treatment with Low Molecular Weight Heparin (LMWH). (abst)Circulation 1995;92(Suppl. 1):I-416.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

    Christopher P. Cannon

Authors
  1. Christopher P. Cannon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher P. Cannon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cannon, C.P. Optimizing the treatment of unstable angina. J Thromb Thrombol 2, 205–218 (1995). https://doi.org/10.1007/BF01062711

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01062711

Key words

Search

Navigation